Those who meet the criteria for inadequate escitalopram response described above will be invited to participate in a six-week trial of supplemental omega-3. Subjects will continue taking escitalopram at the previous dose of 10mg daily but will be randomly assigned to take, in addition, either 0.7 grams or 1.5 grams of the eicosapentaenoic acid (EPA) or a placebo.